Exercise program shows promise for breast cancer recovery
NCT ID NCT04013568
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study looked at whether a 12-week supervised exercise program could improve body composition and physical function in 62 breast cancer patients. Participants exercised 2-3 times per week for 90 minutes. The study measured changes in fat mass, lean mass, bone density, and muscle strength. It also tracked how well patients stuck with exercise after the program ended.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- supervised exercise program
- What this could lead to
- If successful, this could show that structured exercise helps breast cancer patients maintain or improve their body composition and physical function during and after treatment.
- What could go wrong
- This is a small pilot study with only 62 participants and no control group, so results may not be generalizable. The exercise program is intensive and may not be feasible for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
62 people
The number who actually took part.
- Started
-
Aug 2019
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * New diagnosis of breast cancer (within the past 2 years, any subtype, stage I-III) * Can be undergoing neo/adjuvant treatment (surgery, chemotherapy, radiation or endocrine therapy) * Participant is willing and able to comply with the protocol for the duration of the study including undergoing scheduled exercise sessions, completing questionnaires and biometric/biomarker studies * Participant must be able to lie flat on their back for up to 10 minutes * Participant must be able to stand without aid for at least 2 minutes Exclusion Criteria: * Participant with breast cancer recurrence * Metastatic breast cancer * Uncontrolled psychiatric disorder that can affect self-assessment * Pregnant patient * Participants with any internal artifact (e.g. pacemakers, internal fixation, arthroplasty) or other physical impairment that would alter the body composition assessment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Hawaii Cancer Center
Honolulu, Hawaii, 96813, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?